GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » EV-to-Revenue

Stevanato Group SPA (Stevanato Group SPA) EV-to-Revenue : 6.87 (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Stevanato Group SPA's enterprise value is $8,048 Mil. Stevanato Group SPA's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,171 Mil. Therefore, Stevanato Group SPA's EV-to-Revenue for today is 6.87.

The historical rank and industry rank for Stevanato Group SPA's EV-to-Revenue or its related term are showing as below:

STVN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.67   Med: 6.37   Max: 9.73
Current: 6.87

During the past 6 years, the highest EV-to-Revenue of Stevanato Group SPA was 9.73. The lowest was 3.67. And the median was 6.37.

STVN's EV-to-Revenue is ranked worse than
74.88% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.235 vs STVN: 6.87

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-03), Stevanato Group SPA's stock price is $26.81. Stevanato Group SPA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.41. Therefore, Stevanato Group SPA's PS Ratio for today is 6.08.


Stevanato Group SPA EV-to-Revenue Historical Data

The historical data trend for Stevanato Group SPA's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA EV-to-Revenue Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - 6.00 4.53 6.42

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.53 6.56 8.04 7.20 6.42

Competitive Comparison of Stevanato Group SPA's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Stevanato Group SPA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stevanato Group SPA's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SPA's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Stevanato Group SPA's EV-to-Revenue falls into.



Stevanato Group SPA EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Stevanato Group SPA's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8048.253/1170.74
=6.87

Stevanato Group SPA's current Enterprise Value is $8,048 Mil.
Stevanato Group SPA's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,171 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA  (NYSE:STVN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Stevanato Group SPA's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=26.81/4.412
=6.08

Stevanato Group SPA's share price for today is $26.81.
Stevanato Group SPA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.41.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.